Compare

Amgen vs Merck

MonkScore ranges and fundamentals, side by side

Key facts

Amgen and Merck: key facts

  • In fiscal 2025, Amgen Inc. reported revenue of $36.7B and net income of $7.7B.
  • In fiscal 2025, Merck & Co., Inc. reported revenue of $64.9B and net income of $18.3B.
  • Amgen Inc.'s revenue grew 9.1% a year from fiscal 2021 to fiscal 2025.
  • Merck & Co., Inc.'s revenue grew 7.5% a year from fiscal 2021 to fiscal 2025.
  • Amgen Inc.'s free cash flow was positive in 5 of the 5 fiscal years from 2021 to 2025.
  • Merck & Co., Inc.'s free cash flow was positive in 5 of the 5 fiscal years from 2021 to 2025.
  • In the twelve months to 30 June 2026, Amgen Inc. reported revenue of $38.1B and net income of $8.7B.
  • In the twelve months to 30 September 2026, Merck & Co., Inc. reported revenue of $67.3B and net income of $2.5B.

Side by side

Amgen and Merck, side by side

Each figure is in the company's reporting currency, with its fiscal year or the date of its last report.

FigureAmgen Inc.NASDAQ:AMGNMerck & Co., Inc.NYSE:MRK
MonkScore
MonkScore range90–100as of October 202660–70as of October 2026
Sector rank65 of 628 in Healthcare266 of 628 in Healthcare
How this score is madeDisclaimer
Profile
SectorHealthcareHealthcare
IndustryDrug Manufacturers - GeneralDrug Manufacturers - General
Latest fiscal year
Revenue$36.7BFY 2025$64.9BFY 2025
Net income$7.7BFY 2025$18.3BFY 2025
Free cash flow$8.1BFY 2025$12.4BFY 2025
Operating cash flow$10.0BFY 2025$16.5BFY 2025
Total debt$54.6BFY 2025$50.5BFY 2025
Cash$9.1BFY 2025$14.6BFY 2025
Last 12 months
Revenue$38.1Bto 30 June 2026$67.3Bto 30 September 2026
Net income$8.7Bto 30 June 2026$2.5Bto 30 September 2026
Free cash flow$10.2Bto 30 June 2026$16.1Bto 30 September 2026
Operating cash flow$12.5Bto 30 June 2026$20.0Bto 30 September 2026
Total debt$57.3Bto 30 June 2026$53.9Bto 30 September 2026
Cash$14.0Bto 30 June 2026$6.8Bto 30 September 2026

MonkStreet provides research, not investment advice.